I received my Doctor of Medicine degree from the School of Medicine, Zhejiang University. Currently, I am the Director of the Breast Surgery Department and serve as a doctoral supervisor. I have devoted more than three decades to breast cancer research. My research mainly centers on the mechanisms of chemoresistance in breast cancer and strategies for immune cell therapy. Concerning chemoresistance, my research explores the role of the eIF5A-2/ROS signaling pathway in regulating autophagy during epithelial- mesenchymal transition (EMT) - mediated chemotherapy resistance in breast cancer. In the domain of cellular immunotherapy, I focus on the development and clinical translation of novel HER2-targeting CAR-NK cells, aiming to improve their survival, chemotactic ability, and antitumor efficacy within the breast tumor microenvironment. 

Proficient in the comprehensive diagnosis and management of benign and malignant breast diseases, including various breast cancer surgeries (modified radical mastectomy, breast-conserving surgery combined with oncoplastic reconstruction, autologous or implant-based breast reconstruction, endoscopic breast cancer surgery, etc.), minimally invasive excisional biopsy of breast masses, as well as systemic therapy for breast cancer, along with follow-up and holistic management throughout the disease course.

China Cancer Original Research Award（2019）

Standing Committee Member of Breast Cancer Expert Committee of Chinese Society of Clinical Oncology

Standing Committee Member of Breast Diseases Professional Committee of Chinese Medical Education Association

Member of Breast Surgery Group, Surgery Society of Chinese Medical Association

Member of Breast Cancer Professional Committee of China Anti-Cancer Association